RYTM Stock Overview
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
Rhythm Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.35|
|52 Week High||US$21.00|
|52 Week Low||US$3.04|
|1 Month Change||29.46%|
|3 Month Change||-61.20%|
|1 Year Change||-79.02%|
|3 Year Change||-80.23%|
|5 Year Change||n/a|
|Change since IPO||-85.50%|
Recent News & Updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|RYTM||US Biotechs||US Market|
Return vs Industry: RYTM underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: RYTM underperformed the US Market which returned -18.4% over the past year.
|RYTM Average Weekly Movement||14.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RYTM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: RYTM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company’s lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders.
Rhythm Pharmaceuticals Fundamentals Summary
|RYTM fundamental statistics|
Is RYTM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RYTM income statement (TTM)|
|Cost of Revenue||US$825.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.30|
|Net Profit Margin||-3,598.14%|
How did RYTM perform over the long term?See historical performance and comparison
Is RYTM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RYTM?
Other financial metrics that can be useful for relative valuation.
|What is RYTM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does RYTM's PS Ratio compare to its peers?
|RYTM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: RYTM is good value based on its Price-To-Sales Ratio (47.5x) compared to the peer average (532.8x).
Price to Earnings Ratio vs Industry
How does RYTM's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: RYTM is expensive based on its Price-To-Sales Ratio (47.5x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is RYTM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||47.5x|
|Fair PS Ratio||25.3x|
Price-To-Sales vs Fair Ratio: RYTM is expensive based on its Price-To-Sales Ratio (47.5x) compared to the estimated Fair Price-To-Sales Ratio (25.3x).
Share Price vs Fair Value
What is the Fair Price of RYTM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RYTM ($4.35) is trading below our estimate of fair value ($140.46)
Significantly Below Fair Value: RYTM is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RYTM's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Rhythm Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYTM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RYTM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RYTM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RYTM's revenue (64.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: RYTM's revenue (64.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RYTM is forecast to be unprofitable in 3 years.
Discover growth companies
How has Rhythm Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RYTM is currently unprofitable.
Growing Profit Margin: RYTM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RYTM is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare RYTM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: RYTM has a negative Return on Equity (-70.46%), as it is currently unprofitable.
Discover strong past performing companies
How is Rhythm Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RYTM's short term assets ($253.4M) exceed its short term liabilities ($47.3M).
Long Term Liabilities: RYTM's short term assets ($253.4M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: RYTM is debt free.
Reducing Debt: RYTM has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYTM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RYTM has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 32.9% each year.
Discover healthy companies
What is Rhythm Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RYTM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RYTM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RYTM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RYTM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RYTM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Meeker (67 yo)
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD6.46M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: RYTM's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: RYTM's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rhythm Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Rhythm Pharmaceuticals, Inc.
- Ticker: RYTM
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$219.213m
- Shares outstanding: 50.39m
- Website: https://www.rhythmtx.com
Number of Employees
- Rhythm Pharmaceuticals, Inc.
- 222 Berkeley Street
- 12th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.